Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
Richard Marsden, CEO of Synairgen, said: We are delighted that our inhaled interferon beta formulation has been entered into this US Government-funded Phase II/III study and that dosing has now commenced.
- Richard Marsden, CEO of Synairgen, said: We are delighted that our inhaled interferon beta formulation has been entered into this US Government-funded Phase II/III study and that dosing has now commenced.
- We look forward to tracking the progress of the ACTIV-2 trial alongside our other COVID-19 trials.
- The adaptive nature of the ACTIV-2 trial allows for comparison of multiple interventions with a shared group of placebo recipients.
- Synairgen is also running an international 610 patient Phase III trial, which is progressing well, assessing the efficacy of inhaled interferon beta in hospitalised patients with COVID-19.